A letter from the FED UP! Coalition Chair:
Dear Friends of the FED UP! Coalition,
Serving as Chair of the FED UP!
FED UP! began its advocacy work at a time when few Americans knew what an “opioid” was. But, as overdose deaths attributed to the overprescribing of opioids increased, awareness of the crisis grew. FED UP!’s rallies and other efforts led to successes, including an invitation to the White House for President Obama’s 2016 signing of the first Federal legislation that would provide meaningful funding to the states for opioid addiction treatment. Today we would be hard-pressed to find someone who doesn’t know that we have an opioid crisis … so our movement has definitely brought awareness. However, stronger illicit opioids like fentanyl have recently appeared, and overdose deaths are continuing to rise. Recent Federal legislation has brought some significant positive change, but change at the FDA and funding for opioid addiction treatment are both still desperately needed … and Pharma must be held accountable for the role they have played in the epidemic.
In recognition of the need for FED UP!’s important work to continue, and of my having reached a stage in life that makes it difficult for me to spend the time required to lead this effort, I have decided that I will retire from my position as Chair of FED UP!, a position I have held since the inception of the Coalition. This was not an easy decision, and I plan to remain involved at a level that works for both me and for FED UP! Emily Walden has been voted in as the new Chair of FED UP! effective January 1, 2019. She is the right person at the right time for this job! Her passion and knowledge will bring new awareness and energy to address the issues and lead FED UP!. I hope that you will support Emily’s efforts and offer to help her in any way you can.
It is difficult to know where to begin with my thank-yous to the countless individuals and organizations that have helped me in my role as Chair of FED UP!. I would especially like to thank the other members of the amazing and hard-working FED UP! Executive Committee: Andrew Kolodny, April Rovero, Dan Busch, Emily Walden, Karen Carlini, and Lexi Reed Holtum. But I THANK YOU all for making my time as Chair of the FED UP! Coalition a time of special friendships and rewarding work! I am grateful for the opportunity I was given to serve in this capacity, and I know I will miss it.
Founder and Past-Chair of the FED UP! Coalition
On Dec. 17th and 18th, a joint FDA Advisory Committee met to discuss accessibility of naloxone, the opioid-overdose antidote. Following a Call To Action posted by the FED UP! Coalition several weeks ago, hundreds of comments had been submitted to the docket for the Advisory Committee’s review prior to the meeting.
Representatives and staff of the FED UP! Coalition attended the hearing and met with industry, advisory committee members and other harm reduction activists.
Much of the Advisory Committee discussion revolved around how naloxone could best be distributed to those who need it. This discussion involved such issues as the need for a Federal Government response that will assure a “stable and affordable supply of many millions of doses” “procured by the federal government” for [distribution through] various channels. Emphasis was placed by many of the Committee members on the need to support community-based distribution programs. Barriers to naloxone access include the cost of naloxone, state naloxone accessibility laws, lack of generic alternatives for the intranasal and auto-injector forms of naloxone, lack of over-the-counter naloxone.
Most emphasis regarding the outcome of the Committee meeting has been on the vote on FDA labeling language regarding co-prescribing. This is because the only question on which the Committee was asked to vote was the following: “Would labeling language that recommends co-prescription of naloxone for all or some patients prescribed opioids, or more targeted prescribing for patients otherwise at high risk for death from opioid overdose be an effective method for expanding access to naloxone and improving public health?” Those situations in which the FDA would recommend co-prescribing were not specified.
Co-prescribing of naloxone means that for all or some patients naloxone would be prescribed along with their prescription for opioids. The major purpose of co-prescribing is to place naloxone in the hands of those patients at greater risk for an opioid overdose. An additional major benefit to co-prescribing is the conversation between the physician and patient. This dialogue provides an opportunity to educate patients in how to recognize and reverse an opioid overdose and extends a gateway for other conversations regarding opioid use disorder and other risks of opioids.
Some of the concerns with naloxone co-prescribing include the cost, effectiveness of the model, and stock of the medication. A major concern regarding the effectiveness of the co-prescribing model is that the majority of opioid overdoses are now due to illicit fentanyl, and co-prescribing will not properly target the group of people who use illicit opioids.
The Committee ultimately voted 12-11 in favor of the single question the FDA had asked it to vote on.
However, the comments of the Committee members regarding their votes show that many of them saw co-prescribing as less important in the overall public health effort than assuring measures such as inexpensive over-the-counter availability of naloxone and assuring an adequate supply of naloxone to community-based distribution networks.
Comments taken from two of those who voted “Yes” to co-prescribing language demonstrate this:
Dr. Daniel Ciccarone of UCSF said, “What we really need is to support our friends in the community who are doing great work over multiple years, we need OTC switch, we need federal stockpiling, we need parity in the injection versus intranasal labeling; we need generics.”
Dr. Brian Bateman of Harvard said, “This is really not the most important issue with respect to naloxone. What’s emerged from the discussion is that we need a way of getting inexpensive naloxone to community based programs and finding a sustainable model for funding that and lowering all of the barriers that might impede that.”
It should also be noted that for a prescription medication to become an over-the-counter product, a manufacturer must submit a consumer-friendly drug facts label (DFL) and proper study which illustrates the medication is easily administered or taken without the assistance of a medical professional. The FDA has developed a model DFL and now waits for a manufacturer to submit an OTC naloxone product for review. This is the first time the FDA has proactively developed a model DFL. FDA representatives at the December meeting mentioned there has been great interest among manufacturer and once something is formally submitted it will be fast-tracked to become an OTC product. The concern still lies with insurers covering an OTC product, indicating an OTC framework is not a panacea to increasing accessibility of naloxone.
The FED UP! Coalition advocated for:
- All forms of naloxone to be sold over the counter
- The Federal government to subsidize over the counter naloxone to keep the price under $20 per dose.
- The Federal government to launch a public awareness campaign regarding Naloxone to cover such issues as:
- Should you have naloxone in your home or place of business?
- How do you know when to administer naloxone?
- How do you administer naloxone?
The day after the FDA Advisory Committee Meeting, HHS issued a Guidance called: “Naloxone: The Opioid Reversal Drug that Saves Live.” Included it in are the following co-prescribing recommendations:
“In order to reduce the risk of overdose deaths, clinicians should strongly consider prescribing or coprescribing naloxone, and providing education about its use for the following patients who are at risk of opioid overdose:
- Patients prescribed opioids who:
- Are receiving opioids at a dosage of 50 morphine milligram equivalents (MME) per day or greater;
- Have respiratory conditions such as chronic obstructive pulmonary disease (COPD) or obstructive sleep apnea (regardless of opioid dose);
- Have been prescribed benzodiazepines (regardless of opioid dose).
- Have a non-opioid substance use disorder, report excessive alcohol use, or have a mental health disorder (regardless of opioid dose).
- Patients at high risk for experiencing or responding to an opioid overdose, including individuals:
- Using heroin, illicit synthetic opioids or misusing prescription opioids.
- Using other illicit drugs such as stimulants, including methamphetamine and cocaine, which could potentially be contaminated with illicit synthetic opioids like fentanyl.
- Receiving treatment for opioid use disorder, including medication-assisted treatment with methadone, buprenorphine, or naltrexone.
- With a history of opioid misuse that
wererecently released from incarceration or other controlled settings where tolerance to opioids has been lost.”
A special thank you to those who’ve pioneered and progressed overdose prevention and harm reduction initiatives and increased naloxone accessibility in communities across America, including:
- Eliza Wheeler and Sharon Stancliff
- Lexi Reed Holtum and Randy Anderson
- Alexander Walley
- Phillip Coffin
- Maya Doe-Simkins
- Corey Davis
- Traci Green
- Dan Bigg
- Jeffrey Bratberg
- Chad Sabora
- Robert Childs
- Andrew McAuley
- Daniel Raymond
- Robert Riley
- And the many others.
The FDA is looking into how naloxone can be made more available. They’ll be having an Advisory Committee meeting on December 17th and 18th to discuss this matter.
The FED UP!
The FED UP! Coalition plans to communicate to the FDA:
- All forms of naloxone should be sold over the counter
- The Federal government should subsidize over the counter naloxone to keep the price under $20 per dose.
- The Federal government should launch a public awareness campaign regarding Naloxone to cover such issues as:
- Should you have naloxone in your home or place of business?
- How do you know when to administer naloxone?
- How do you administer naloxone?
The FDA is also asking what has worked in your community to expand naloxone access and in what circumstances you believe that naloxone should automatically be prescribed when an opioid is prescribed. You may want to let them know your opinion on these issues as well.
Comments sent by Friday, Dec. 14, 2018, will be reviewed by the FDA Advisory Committee.
One year ago, President Trump declared the opioid crisis a public health emergency. On Wednesday, the opioid package was signed into law with $8.5 billion allocated for opioid solutions. This will
Key components of the bill include funding for addiction treatment, recovery housing and job training for people with substance use disorder and a lift on an outdated rule which barred Medicaid from covering addiction treatment in facilities with more than 16 beds. Expanding access to
With fentanyl now the leading cause of opioid overdoses in our country, measures to tighten postage tracking will also be implemented.
The bill allocates the money over the next year. Although the bill is an excellent step in the right direction and an example of bipartisan cooperation to address the crisis, until addiction is treated as a disease by society and truly confronted as a public health emergency, we will continue to see an influx of overdose deaths and the number of individuals suffering from the disease of addiction. Fighting systemic injustices is critical. Insurers upholding parity, coverage of addiction treatment, standards of care for recovery residences, compassion and care towards those who use opioids to manage pain, reducing addiction stigma; all are essential changes we need.
The funds are simply not enough. Hundreds of billions are needed over multiple years. A proposal by Sen. Warren and Sen. Cummings would have done just that. Modeled after the Ryan White CARE Act, legislation that funded solutions and support for communities impacted by HIV/AIDS, the Warren-Cummings proposal called for $100 billion over 10 years. This proposal was not included in the final opioid bill. With more attention to treatment for opioid use disorder, it’s important for us to also advocate for recovery services. Recovery for the individual and the family.
These funds would never have been made available without you. You called, emailed, showed up, and told your stories. We, as a coalition, work together as individuals and organizations to advocate for these changes, to save lives, to deliver compassion to our communities. Only together are we a powerful constituency, a unified message, a coalition. We have a lot of work ahead of us. Today, the Ensuring Patient Access and Drug Enforcement Act still stands, the FDA continues to approve new, highly potent opioids, and overdose deaths continue to soar.
We will continue to demand Federal action, to rally in cities across the country, and raise our voices. We’ll push forward in our local communities with the work of our organizations and the advocacy of the individuals demanding change.
Richard Sackler, the former Chairman and President of Purdue Pharma, and Rhodes Pharmaceutical (a subsidiary of Purdue Pharma) have been awarded a patent for treatment of opioid use disorder, the disorder the Sackler family and Purdue Pharma knowingly fueled along with overdose, death and family tragedy.
At a minimum the patent should serve the public good and provide no economic benefit to the Sackler Family.
The patent petition ignores Purdue Pharma’s role and responsibility for creating the need for the invention. The application for the patent (Patent no. 9861628) includes the following:
“Chronic pain, which may be due to idiopathic reasons, cancer or other diseases such as rheumatism and arthritis, is typically treated with strong opioids.
“Thus, if opioids are taken by healthy human subjects with a drug seeking behavior they may lead to psychological as well as physical dependence.”
“One of the fundamental problems of illicit drug use by drug addicts (“junkies”) who are dependent on the constant intake of illegal drugs such as heroin is the drug related criminal activities resorted to by such addicts in order to raise enough money to fund their addiction.”
Outrageous, dishonest and lacking any acknowledgement of responsibility for fueling the opioid epidemic thru deceptive marketing and promotion of Sackler products.
FDA approval of a product made through this patent and a company (Rhodes) set up to obscure the Sackler connection would allow the Sackler family to reap more profits from a treatment for the epidemic caused by Sackler family products.
We cannot allow this to happen.
Sign up for our mailing list today and we’ll let you know how you can help as plans are formulated to make sure that the Sacklers never profit from this new patent.
-By Daniel Busch, MD, Advocacy Chair, FED UP! Coalition
Addiction Policy Forum (APF) and its Founder, CEO, and President, Jessica Nickel, have become a force within the addiction advocacy movement. Ms. Nickel is widely respected. She is bright, capable, and gets things done. In the past year, she has testified before the President’s Opioid Commission and before important congressional committees and subcommittees.
APF now has chapters in 19 states. Twelve of these have been founded since mid-April, 2018. Many of the chapters are led by excellent people devoted to addiction treatment. APF recently launched its Addiction Resource Center, a user-friendly website to locate local addiction treatment resources,
So what’s the problem?
The problem is the relationship between Ms. Nickel and the pharmaceutical industry.
Sign the Change.org petition on holding the Sackler family and Purdue Pharma accountable for the opioid crisis: https://www.change.org/p/hold-
Make plans to have your voice heard and attend the 2018 FED UP! Rally in Washington, D.C. on October 7th. Please contact April Rovero at firstname.lastname@example.org with questions or to volunteer with planning or on event day.
Attend and/or offer to organize a local rally and vigil on International Overdose Awareness Day by contacting email@example.com